The DexCom Inc. (DXCM) Position Increased by Suntrust Banks Inc.

The DexCom Inc. (DXCM) Position Increased by Suntrust Banks Inc.

Suntrust Banks Inc. boosted its stake in shares of DexCom Inc. (NASDAQ:DXCM) by 164.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,717 shares of the medical device company’s stock after buying an additional 4,799 shares during the period. Suntrust Banks Inc.’s holdings in DexCom were worth $675,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the stock. BNP Paribas Arbitrage SA increased its stake in shares of DexCom by 3,320.0% in the third quarter. BNP Paribas Arbitrage SA now owns 1,197 shares of the medical device company’s stock valued at $105,000 after buying an additional 1,162 shares during the last quarter. Bellwether Investment Group LLC purchased a new stake in shares of DexCom during the second quarter valued at approximately $119,000. Global X Management Co. LLC increased its stake in shares of DexCom by 118.9% in the third quarter. Global X Management Co. LLC now owns 1,900 shares of the medical device company’s stock valued at $167,000 after buying an additional 1,032 shares during the last quarter. Capstone Asset Management Co. purchased a new stake in shares of DexCom during the third quarter valued at approximately $205,000. Finally, Accredited Investors Inc. purchased a new stake in shares of DexCom during the third quarter valued at approximately $207,000.

DexCom Inc. (NASDAQ:DXCM) traded down 3.05% during mid-day trading on Thursday, hitting $81.59. 1,787,333 shares of the stock were exchanged. The stock’s 50-day moving average is $66.00 and its 200 day moving average is $79.17. The company’s market capitalization is $6.90 billion. DexCom Inc. has a 52 week low of $47.92 and a 52 week high of $96.38.

Several equities research analysts have commented on the stock. Morgan Stanley downgraded shares of DexCom from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $87.00 to $66.00 in a research note on Tuesday, January 3rd. B. Riley reissued a “neutral” rating and set a $84.00 price objective on shares of DexCom in a research report on Monday, November 7th. Zacks Investment Research raised shares of DexCom from a “sell” rating to a “hold” rating in a research report on Monday, January 9th. Canaccord Genuity reissued a “buy” rating on shares of DexCom in a research report on Tuesday, January 10th. Finally, Wedbush reissued an “outperform” rating and set a $112.00 price objective (up previously from $100.00) on shares of DexCom in a research report on Wednesday, November 2nd. Three research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. DexCom presently has a consensus rating of “Buy” and a consensus target price of $89.60.

In other DexCom news, EVP Richard Doubleday sold 3,182 shares of the business’s stock in a transaction on Friday, December 23rd. The shares were sold at an average price of $62.17, for a total transaction of $197,824.94. Following the completion of the sale, the executive vice president now owns 83,582 shares in the company, valued at approximately $5,196,292.94. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Steven Robert Pacelli sold 10,300 shares of the business’s stock in a transaction on Monday, October 24th. The shares were sold at an average price of $81.95, for a total transaction of $844,085.00. The disclosure for this sale can be found here. Insiders have sold a total of 55,053 shares of company stock worth $3,968,013 in the last quarter. 2.80% of the stock is owned by corporate insiders.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom Inc. (NASDAQ:DXCM).

Related posts

Leave a Comment